The FDA's move to incorporate Bayesian statistical methods into clinical trials of drugs and biologics garnered special treatment in JAMA this week. UW Professor of Biostatistics Thomas Fleming weighs in with his thoughts.
News & Events
Latest
Are Bayesian Statistics Coming to a Clinical Trial Near You?
MEDPAGE TODAY,
New Podcast Calls Attention to Underrecognized IRGT Trial Design
NIH Pragmatic Trials Collaboratory,
In a new episode of the NIH Collaboratory Podcast, Drs. Jonathan Moyer and David Murray discussed their recent publication, “Evaluating Analytic Models for Individually Randomized Group Treatment Trials With Complex Clustering in Nested and Crossed Designs.” The episode was moderated by Patrick Heagerty, co-chair of the Biostatistics and Study Design core working group and professor of biostatistics at the University of Washington.
Ali Shojaie awarded a $3M grant from the National Institutes of Health (NIH) to find a way to diagnose Alzheimer’s disease and related dementias long before symptoms appear.
Reflections on FDA Draft Guidance on Bayesian Methods in Trials—Protecting Scientific Integrity and Evidentiary Standards
JAMA Perspective,
University of Washington Professor of Biostatistics Thomas Fleming and Affiliate Professor Holly Hanes reflect on the FDA's recently released draft guidance regarding the use of bayesian methods in clinical trials.
The weed-killer wars
The Week,
Trump wants the U.S. to ramp up production of glyphosate. The MAHA movement is furious. Lianne Sheppard, Professor of Biostatistics and Environmental and Occupational Health Sciences weighs in on the herbicide’s safety.